Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results
At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.
- At the AASLD Liver Meeting next week, we will present a comprehensive analysis of noninvasive tests and imaging from the MAESTRO-NASH trial.
- The Agency noted that it is not currently planning to hold an advisory committee meeting to discuss the application.
- In October 2023, we completed a public offering and received an additional $472.0 million in net cash proceeds.
- These increases in interest income were due primarily to higher average interest rates in 2023.